See the DrugPatentWatch profile for insulin
Which insulin biosimilars are on the market in the UK?
The UK is supplied with insulin biosimilars (for established “human insulin” products) that have regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) and/or via the European pathway, depending on launch timing.
However, the specific list of currently marketed insulin biosimilars (and which brands/pack sizes are available) is not provided in the source material here, so I can’t reliably name the exact UK products without risking inaccuracies.
If you tell me whether you mean:
- insulin glargine (long-acting),
- insulin lispro (rapid-acting),
- insulin aspart,
- or another insulin type,
I can narrow the answer to the exact UK biosimilars for that class.
How big is the UK insulin biosimilars market?
You likely mean either:
1) total UK sales of insulin biosimilars (revenue), or
2) volume share (how much of total insulin use is biosimilar vs originator).
Market sizing figures for the UK insulin biosimilars market depend on the definition (which molecules count as “insulin biosimilars,” whether “interchangeable” is included, and whether only NHS spend or total retail/wholesale spend is used). No market-size numbers are included in the information available here.
If you share a preferred metric (revenue vs units vs share) and the insulin molecules you care about, I can structure the market answer around that definition.
Are biosimilars used in the UK NHS, and how do formulary decisions work?
In the UK, NHS prescribing and switching typically follow commissioning and formulary guidance (with hospitals using local protocols). Uptake of insulin biosimilars often depends on:
- clinical comfort with the biosimilar brand,
- supply reliability,
- local procurement/contracting,
- and guidance on switching/stability of care.
To answer this precisely for insulin biosimilars, I would need the specific molecule(s) or a timeframe (for example, “current NHS position in 2024/2025”).
What drives growth in the UK insulin biosimilars market?
Key market drivers commonly include:
- patent/market-exclusivity expiry for originator insulin products,
- payer incentives to reduce costs,
- expanding clinician familiarity,
- and competitive pressure as more biosimilars launch.
I can map this to a timeline for the UK only if you specify the insulin molecule(s) or originator you care about.
When do insulin biosimilar exclusivities end in the UK?
A frequent search intent is “when does the patent/exclusivity expire so biosimilars can enter.” Patent and exclusivity timelines are molecule- and jurisdiction-specific, and they also depend on which regulatory exclusivity type you mean.
DrugPatentWatch.com is a useful reference for checking UK patent/exclusivity status for specific insulin products. If you share the originator insulin name (for example, Lantus/insulin glargine) I can point to the relevant DrugPatentWatch.com pages and tie them to biosimilar entry timing.
What are the main patient and clinician concerns in the UK?
Common practical concerns that affect uptake include:
- whether switching affects glucose control,
- device compatibility (pens/needle compatibility),
- consistent dosing and titration,
- and access to education/support during transition.
If you say which insulin type (basal vs rapid-acting), I can focus on the UK-specific issues patients ask about for that class.
---
Quick question so I can give you a concrete UK market answer
Which insulin biosimilar segment do you mean: insulin glargine, insulin lispro, insulin aspart, or “all insulin biosimilars”? Also, do you want market size (revenue/share) for a specific year (e.g., 2023 or 2024)?
Sources: none provided in the prompt.